Her highly cited research program investigates mechanisms behind epigenomic plasticity and how plasticity contributes to tumor initiation and progression. She is interested in how both genetic driver mutations and environmental toxicant exposures can reprogram the epigenome, increasing stemness and contributing to cancer progression. Using -omics level approaches, her team studies transcriptome (RNA-sequencing), methylome (Illumina EPIC DNA methylation arrays), and global chromatin changes (ATAC-sequencing) in normal, pre-malignant, and malignant cell populations in response to genetic and environmental insults. The work is aimed at identifying novel therapeutic strategies for the treatment of aggressive human cancers based on their molecular profiling and to determine whether epigenetic therapies are effective at augmenting standard of care for specific subsets of patients.